Form 4: Compass Therapeutics Director Granted Stock Options

Compass Therapeutics director Richard S. Lindahl received a grant of 90,000 stock options with an exercise price of $5.17, vesting by June 2026 or the next annual meeting.

Summary

• Richard S. Lindahl, a Director of Compass Therapeutics, Inc. (CMPX), was granted 90,000 stock options.
• The transaction date for this grant was January 2, 2026.
• Each option has an exercise price of $5.17.
• The options are exercisable starting January 2, 2026, and will expire on January 2, 2036.
• The grant vests in full upon the earlier of June 10, 2026, or the date of the Company's next annual meeting of stockholders.
• Following this transaction, Mr. Lindahl beneficially owns 90,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the option grant aligns director incentives with shareholder interests, which is generally viewed favorably. It's a routine compensation event, not indicative of major operational news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule provides an incentive for continued service and contribution to the company's strategic goals.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholder equity, although this is a standard aspect of equity compensation plans.

Future Outlook

The vesting conditions for the stock options, tied to either a specific date or the next annual meeting, indicate a forward-looking incentive structure designed to retain and motivate the director for future contributions to the company's performance.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, where long-term incentives are crucial for attracting and retaining experienced leadership. This type of compensation structure is designed to align the interests of directors with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• Equity compensation, particularly through stock options, is a standard component of director remuneration across the biotech sector, including companies comparable to Compass Therapeutics.
• The exercise price of $5.17, being the market price at the time of grant, is typical for incentive stock options.
• Vesting schedules tied to service or corporate events like annual meetings are also standard practice, ensuring continued commitment from board members.

Related Party Transactions

• The grant of 90,000 stock options to Richard S. Lindahl, a Director of Compass Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned director incentives; minor potential for dilution if options are exercised.
• Director (Richard S. Lindahl): Receives a significant equity incentive, aligning personal financial success with the company's performance.

Next Steps

• The stock options will vest in full upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the specified exercise price until the expiration date.

Key Dates

Keywords

Compass Therapeutics, CMPX, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Form 4, Beneficial Ownership